Letaplimab represents a distinct clinical strategy for treating complement-mediated diseases. This antibody targets complement component C1q, a key component of the complement pathway, potentially block its first https://stevesazl055471.mpeblog.com/73646184/letaplimab-a-innovative-therapeutic-strategy